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Age-related features of the pathogenesis of ischemic heart 
disease and sensitivity of patients’ DNA to cytoprotectors
Nina I. Zhernakova*, Olesya V. Romaschenko, Peter K. Alferov, Eduard A. Snegin, Vadim V. Rumbesht, 
Natalia D. Grischenko
INTRODUCTION
Ischemic heart disease is a worldwide disease, the main 
cause of death in elderly and senile patients.[1] With 
age, the risk of cardiovascular complications increases 
significantly, which is reflected in the Systematic 
Coronary Risk Evaluation scale, where this factor is 
one of the keys.[2] Perhaps this is due to the stress-
age syndrome, which occurs in the aging process 
and causes the disease to worsen.[3] It is known that 
the aging process is accompanied by the destruction 
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of cellular structures - membranes, mitochondria, 
DNA, which limits the adaptive capacity of the 
body, contributes to the development of age-related 
pathology, and increases the likelihood of death.[3-5]
The accepted standards of medical and surgical 
treatment cannot fully solve the problem. An 
attempt to significantly increase the effectiveness of 
treatment is the introduction into clinical practice of 
cytoprotective therapy aimed at protecting myocardial 
cells from ischemic damage.[6] Cytoprotectors have a 
preconditioning effect and can increase cell viability 
under hypoxic conditions.[7] Means of metabolic 
therapy are recommended for use in patients of older 
age groups as geroprotectors,[8] they reveal their 
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positive effect when administered in the combination 
treatment of IHD and CHF in elderly and senile 
patients.[9]
Perhaps the use of cytoprotectors in old age has 
double feasibility - protects the cells of the heart from 
ischemic damage and slows down the aging process.
It is of interest to study cytoprotectors with different 
metabolic orientations: Meldonium as a drug that 
switches myocardial energy exchange from the 
consumption of fatty acids to the extraction of energy 
from carbohydrates; phosphocreatine as a drug that 
activates the process of substrate phosphorylation, 
and cytoflavin as a combination drug that activates the 
process of aerobic glycolysis.
The degree of cell DNA destruction can be classically 
estimated by the comet assay.[10] In our previous 
works, we showed that cytoprotectors have a certain 
effect on the DNA of blood leukocytes in patients 
with coronary artery disease.[11] Whether there are age-
related features of DNA, sensitivity to cytoprotectors 
is the topic of the present study.
The objective of this research was to study the age-
related features of the pathogenesis of coronary heart 
disease (CHD) and the sensitivity of patients’ DNA 
to cytoprotectors: Meldonium, phosphocreatine, and 
cytoflavin.
MATERIALS AND METHODS
To achieve the objective of the study, we conducted 
a randomized, open controlled clinical study of 
160 patients with coronary artery disease: Stable 
exertional angina (117 men and 43 women). Patients 
were divided into two groups depending on age: The 
Group 1 consisted of 82 patients of middle age (from 
45 to 60 years, on average 51.56 ± 0.61 years) and 
Group 2 - 78 elderly patients (from 60 to 75 years 
old, on average 66.76 ± 0.57 years). The clinical 
examination of patients in the original status took 
place on their admission in the Department of 
Cardiology №1 of St. Joasaph Belgorod Regional 
Clinical Hospital. Each participant was made aware of 
the research program and signed an informed consent. 
In the majority of patients, angina was combined with 
hypertension (89.4%), rhythm disturbances (24.4%), 
post-infarction cardiosclerosis (48.8%), chronic 
heart failure (94.4%), and in some patients - with 
type II diabetes mellitus (23.1%). The program of 
examination of patients included the implementation 
of general clinical, instrumental and laboratory 
research methods, including electrocardiography, 
Doppler echocardiography, coronary angiography 
(CAG), treadmill test, general, and biochemical 
blood tests according to the recommendations of the 
All-Russian Scientific Society of Cardiology and the 
European Society of Cardiology (2013).[6] In addition, 
we studied the metabolic profile of serum ATP 
concentration by the spectrophotometric method,[12] 
the effect of metabolic series drugs (meldonium, 
phosphocreatine, and cytoflavin) on the cell DNA 
was evaluated by the comet assay by testing the drugs 
in vitro using the method developed by us.[13] A number 
of indicators were determined using the comet assay: 
The comet DNA index, the percentage of DNA in 
the comet tail, the maximum degree of DNA damage 
(from 1 to 4 points). Studies of the comet assay were 
performed in the laboratory of population genetics 
and genotoxicology of the BelSU National Research 
University.
Only reliable data were entered into the summary 
tables for further analysis. Statistical processing of the 
material was performed by the method of variation 
statistics. Quantitative indicators were evaluated for 
compliance with the normal distribution using the 
Kolmogorov–Smirnov test.[14] For the indicators that 
have a distribution close to normal, the arithmetic 
mean, standard (rms) deviation, and mean error 
were calculated. For quantitative indicators with a 
distribution other than normal, as well as for ordinal 
indicators, the mean, median, 25% and 75% quartiles 
were calculated. The difference between the two 
groups was evaluated using the Student’s t-test, the 
Mann–Whitney U-test. Results were considered 
statistically significant at P < 0.05. We used the χ2 
criterion to assess the compliance of the sample 
distribution to predetermined distributions (Hardy-
Weinberg law). Comet Assay software was used to 
evaluate the results of the DNA comets assay. For 
the calculations, Microsoft Excel 2007 and Statistical 
Package for the Social Sciences for Windows 11.0 
were used.
RESULTS AND DISCUSSION
A comparative analysis was conducted between two 
groups of patients of middle and old age. A number 
of reliable differences were obtained [Tables 1 and 2].
Comparison of patients of different age groups showed 
the presence of pathogenetic features of CHD in the 
elderly. Elderly patients have a decrease in height 
and body weight, a longer history of concomitant 
diabetes, with a greater degree of severity. Elderly 
patients smoke 5 times less, however, they have 
significantly more pronounced atherosclerosis 
of the coronary vessels and aorta: According to 
CAG, the average degree of stenosis of almost 
all vascular heart territories is twice as high in the 
elderly (41.09 ± 2.75%), and the number of affected 
coronary arteries is higher, and averages 4 vessels. 
In elderly patients, significantly lower serum ATP is 
observed, which indicates the presence of involutive 
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hypoergosis due to the development of mitochondrial 
dysfunction in the aging process.[14]
We revealed the unequal sensitivity of the genetic 
apparatus of the cells of patients of different age groups 
to the introduction of metabolic correctors, as shown 
in Figure 1 and Table 2. Thus, the introduction of 
meldonium, phosphocreatine, and cytoflavin into the 
sample with a leukocyte suspension in vitro in elderly 
patients is accompanied by the appearance of DNA in 
the tail of the comets in a significantly smaller number 
compared with patients of middle age, which indicates 
a more favorable effect of metabolic correctors on the 
genetic apparatus of the cell in elderly patients.
The data obtained may indicate the presence of the 
geroprotective properties of the drugs we studied, and 
this does not depend on their metabolic orientation.
Table 1: A comparative analysis of indicators of pathogenetic features of CHD in patients of middle and old age
Indicator Middle-age patients, n=82 Old-age patients, n=78 P
Average age, years 51.56±0.61 66.76±0.57 0.001
Height, m 1.71±0.01 1.68±0.01 0.032
Weight, kg 93.46±2.39 84.33±1.60 0.002
DM: Duration in years 0.72±0.29 2.11±0.55 0.029
Smoking: Number of cigarettes per day 10.35±1.46 2.84±0.65 0.001
Quetelet index, kg/m2 31.87±0.76 29.81±0.51 0.026
EchoCG: AV pressure gradient, mm Hg. 6.39±0.41 8.91±0.69 0.002
EchoCG: AV regurgitation 0.51±0.07 0.81±0.10 0.015
CAG: The degree of stenosis of the LCA trunk, % 13.33±3.24 23.11±4.29 0.072
CAG: The degree of the AIVA stenosis, % 51.00±5.03 64.33±4.08 0.042
CAG: The degree of the CA stenosis, % 31.67±4.42 58.00±5.47 0.001
CAG: The degree of the DB stenosis, % 25.00±4.68 47.11±5.09 0.002
CAG: The degree of the AI stenosis, % 6.80±2.61 23.89±5.39 0.005
CAG: The degree of the RCA stenosis, % 38.53±5.37 55.33±5.58 0.033
CAG: Moderate stenosis, % 24.40±2.44 41.09±2.75 0.001
CAG: Number of affected arteries 3.04±0.25 4.33±0.19 0.001
ATP serum, µmol/l 227.39±4.34 207.20±3.52 0.001
The significance of differences was assessed by Student’s t-test. DM: Diabetes mellitus, AV: Aortic valve, LCA: Left coronary artery, AIVA: Anterior 
interventricular artery, CA: Circumflex artery, DB: Diagonal branch, AI: Artery intermedia, RCA: Right coronary artery. EchoCG: Echocardiography
Table 2: A comparative analysis of indicators of pathogenetic features of CHD in patients of middle and old age
Indicator Middle-age patients, n=82 Old-age patients, n=78 P
DM: Severity 0.30/0.00 (0.00;0.00) 0.55/0.00 (0.00;0.88) 0.079
DNA: DNA comet index 0.33/0.14 (0.02;0.50) 0.16/0.03 (0.00;0.10) 0.022
DNA: Meldonium: Maximum damage 2.63/3.00 (2.00;4.00) 1.86/2.00 (1.00;3.00) 0.032
DNA: Phosphocreatine: DNA comet index 0.76/0.40 (0.04;0.98) 0.30/0.08 (0.00;0.42) 0.028
The numerator is the arithmetic average, the denominator is the median, 25% and 75% quartile. The significance of differences was assessed by the Mann–
Whitney U-test
Figure 1: The percentage of DNA in the tail of a comet of blood leukocytes in patients with coronary artery disease on 
introduction of metabolic correctors into the sample (in vitro testing). The differences significance was assessed by student 
t-test
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Considering the age-related features of the 
pathogenesis of coronary artery disease such as a more 
severe course and involutive hypoergosis in elderly 
patients, we should say that this category of patients, 
first, has a higher need for cytoprotectants, and second, 
the use of the latter in older age groups is of particular 
expediency due to their geroprotective properties.
CONCLUSION
The age-related factor has a significant effect on 
the pathogenesis of CHD: In the elderly, involutive 
hypoergosis is observed, a more pronounced 
atherosclerotic impairment of the coronary vessels with 
the involvement of at least 4 vessels with an average 
degree of stenosis from 23% to 64% (41.09 ± 2.75%), 
a longer history of concomitant diabetes mellitus, with 
greater severity of its course, despite significantly less 
common risk factors for smoking and obesity. The studied 
metabolic correctors (meldonium, phosphocreatine, and 
cytoflavin), according to in vitro testing, have a more 
favorable profile of influence on the DNA of cells in 
elderly patients compared to middle-aged patients, which 
indicates the possibility of their use as geroprotectors.[15]
SUMMARY
1. The age-related factor has a significant effect on 
the pathogenesis of CHD: In the elderly, involutive 
hypoergosis is observed, a more pronounced 
atherosclerotic impairment of the coronary vessels 
with the involvement of at least 4 vessels with 
an average degree of stenosis from 23% to 64% 
(41.09 ± 2.75%), a longer history of concomitant 
diabetes mellitus, with greater severity of its course, 
despite significantly less common risk factors for 
smoking and obesity.
2. The studied metabolic correctors (meldonium, 
phosphocreatine, and cytoflavin), according to 
in vitro testing, have a more favorable profile of 
influence on the DNA of cells in elderly patients 
compared to middle-aged patients, which indicates 
the possibility of their use as geroprotectors.
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